228 related articles for article (PubMed ID: 36216601)
1. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.
Barker N; Judge DP
Am J Cardiol; 2022 Dec; 185 Suppl 1():S43-S50. PubMed ID: 36216601
[TBL] [Abstract][Full Text] [Related]
2. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
3. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
4. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
[TBL] [Abstract][Full Text] [Related]
5. ATTR Epidemiology, Genetics, and Prognostic Factors.
Obi CA; Mostertz WC; Griffin JM; Judge DP
Methodist Debakey Cardiovasc J; 2022; 18(2):17-26. PubMed ID: 35414855
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
7. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.
Ando Y; Waddington-Cruz M; Sekijima Y; Koike H; Ueda M; Konishi H; Ishii T; Coelho T
Orphanet J Rare Dis; 2023 Oct; 18(1):323. PubMed ID: 37828588
[TBL] [Abstract][Full Text] [Related]
8. DISCOVERY: prevalence of transthyretin (
Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS
Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532
[TBL] [Abstract][Full Text] [Related]
9. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
11. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological studies of cardiac amyloidosis in transthyretin type familial amyloid polyneuropathy.
Hattori T; Takei Y; Koyama J; Nakazato M; Ikeda S
Amyloid; 2003 Dec; 10(4):229-39. PubMed ID: 14986482
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin Glu54Leu - an unknown mutation within the Swedish population associated with amyloid cardiomyopathy and a unique fibril type.
Hellman U; Lång K; Ihse E; Jonasson J; Olsson M; Lundgren HE; Pilebro B; Westermark P; Wixner J; Anan I
Scand J Clin Lab Invest; 2019 Oct; 79(6):372-376. PubMed ID: 31169435
[TBL] [Abstract][Full Text] [Related]
14. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
Lyng CS; Gude E; Hodt A; Knudsen EC
Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
[TBL] [Abstract][Full Text] [Related]
15. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients.
Swiecicki PL; Zhen DB; Mauermann ML; Kyle RA; Zeldenrust SR; Grogan M; Dispenzieri A; Gertz MA
Amyloid; 2015; 22(2):123-31. PubMed ID: 26017327
[TBL] [Abstract][Full Text] [Related]
16. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
Gopal DM; Ruberg FL; Siddiqi OK
Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
18. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis.
Batra J; Rosenblum H; Cappelli F; Zampieri M; Olivotto I; Griffin JM; Saith SE; Teruya S; De Los Santos J; Argiro A; Burkhoff D; Perfetto F; Maurer MS
J Card Fail; 2022 Jun; 28(6):950-959. PubMed ID: 34974181
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
